Abstract:An innovative nanotherapy engineering approach is developed to enhance therapeutic effects of stem cells. Engineered mesenchymal stem cells demonstrate prolonged survival time in injured hearts, significantly reduce infarct size, improve cardiac function, and promote cardiac remodeling in mice with myocardial ischemia‐reperfusion injury. These benefits are achieved by attenuating oxidative stress and inflammation, inhibiting cardiomyocyte apoptosis, and facilitating cardiac repair. Myocardial infarction, the most severe manifestation of coronary artery disease, is a leading cause of mortality worldwide. Here, a novel nanotherapy engineering approach is reported for enhancing therapeutic effects of mesenchymal stem cells (MSCs) on myocardial ischemia‐reperfusion (MI/R) injury. An anti‐oxidative and anti‐inflammatory nanotherapy (TPCD NP) is first fabricated. MSCs are successfully engineered with TPCD NP by endocytosis, and TPCD NP engineering does not affect stemness of MSCs. TPCD NP‐internalized MSCs (tn‐MSCs) are resistant to oxidative stress, cytotoxicity, and apoptosis induced by reactive oxygen species (ROS). Under oxidative distress, tn‐MSCs show stronger paracrine activity compared to MSCs. Consistently, tn‐MSCs effectively enhance angiogenesis of endothelial cells under pathological conditions. Also, tn‐MSCs protect cardiomyocytes from ROS‐induced cytotoxicity and apoptosis by improving mitochondrial membrane potential and regulating the p53 signaling pathway. In mice with MI/R injury, the survival time of tn‐MSCs in the injured heart is prolonged, compared to pristine MSCs. Correspondingly, tn‐MSCs more significantly reduce the infarct size, improve cardiac function, and promote cardiac remodeling in MI/R injury mice. Mechanistically, tn‐MSCs alleviate MI/R injury by attenuating oxidative stress and inflammation, inhibiting cardiomyocyte apoptosis, and promoting cardiac repair. Consequently, tn‐MSCs are promising for treating cardiovascular diseases linked to oxidative distress and inflammation.

Dynamic and Label-Free Sensing of Cardiomyocyte Responses to Nanosized Vesicles for Cardiac Oxidative Stress Injury Therapy.

In Vitro Assessing the Risk of Drug-Induced Cardiotoxicity by Embryonic Stem Cell-Based Biosensor

Multifunctional Cardiomyocyte-Based Biosensor For Electrophysiology-Mechanical Beating-Growth Viability Monitoring

Biomimetic and NOS‐Responsive Nanomotor Deeply Delivery a Combination of MSC‐EV and Mitochondrial ROS Scavenger and Promote Heart Repair and Regeneration

Electromechanical Integrated Recording of Single Cardiomyocyte in Situ by Multimodal Microelectrode Biosensing System.

Synchronized Electromechanical Integration Recording of Cardiomyocytes.

Extracellular Vesicles Released by Cardiomyocytes in a Doxorubicin-induced Cardiac Injury Mouse Model Contain Protein Biomarkers of Early Cardiac Injury

Cardiomyocyte electrical-mechanical synchronized model for high-content, dose-quantitative and time-dependent drug assessment

Integrated Cardiomyocyte-Based Biosensing Platform for Electroporation-Triggered Intracellular Recording in Parallel with Delivery Efficiency Evaluation

Universal and Sensitive Drug Assessment Biosensing Platform Using Optimal Mechanical Beating Detection of Single Cardiomyocyte

Engineered nanovesicles mediated cardiomyocyte survival and neovascularization for the therapy of myocardial infarction

Synchronized High-Content Recording of Cardiomyocytes in Vitro by Integrated Cell-Based Biosensor

Real-Time Wireless Sensing of Cardiomyocyte Contractility by Integrating Magnetic Microbeam and Oriented Nanofibers

A Cardiomyocyte-Based Biosensing Platform for Dynamic and Quantitative Investigation of Excessive Autophagy.

A Biosensing System Using a Multiparameter Nonlinear Dynamic Analysis of Cardiomyocyte Beating for Drug-Induced Arrhythmia Recognition

Nanotherapy‐Engineered Stem Cells Alleviate Myocardial Reperfusion Injury by Normalizing the Pathological Microenvironment and Promoting Cardiac Repair

Three-Dimensional Cardiomyocyte-Nanobiosensing System for Specific Recognition of Drug Subgroups

A Powerful Tool in the Treatment of Myocardial Ischemia-Reperfusion Injury: Natural and Nanoscale Modified Small Extracellular Vesicles Derived from Mesenchymal Stem Cells

A cardiomyocyte-based biosensor for antiarrhythmic drug evaluation by simultaneously monitoring cell growth and beating.

Peptide-anchored biomimetic interface for electrochemical detection of cardiomyocyte-derived extracellular vesicles

A dynamic and quantitative biosensing assessment for electroporated membrane evolution of cardiomyocytes